Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
NCT ID: NCT02561000
Last Updated: 2025-04-16
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-05-27
Study Completion Date
2019-09-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding.
A secondary objective is to determine whether patients treated with PZ-128 have fewer cardiac events such as heart attack, bypass surgery or stroke compared with those persons treated with the standard of care.
A secondary objective is to determine whether patients treated with PZ-128 have fewer cardiac events such as heart attack, bypass surgery or stroke compared with those persons treated with the standard of care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
NCT00546260
Myocardial Infarction
TERMINATED
PHASE2
Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
NCT02070471
ST-segment Elevation Myocardial Infarction
COMPLETED
PHASE2
A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
NCT00269880
Angioplasty, Transluminal, Percutaneous Coronary
COMPLETED
PHASE3
Antiplatelet Response, Interval Variability & Events in Percutaneous Coronary Intervention (ARIVE-PCI) Registry
NCT01278043
Coronary Artery Disease
COMPLETED
Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
NCT03048019
Non-ST Elevation Myocardial Infarction (NSTEMI)
TERMINATED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Arterial Occlusive Diseases
Coronary Artery Disease
Coronary Disease
Arteriosclerosis
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Acute Coronary Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PZ-128 0.3 mg/kg
PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
Group Type
EXPERIMENTAL
PZ-128
Intervention Type
DRUG
PZ-128 0.5 mg/kg
PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
Group Type
EXPERIMENTAL
PZ-128
Intervention Type
DRUG
Placebo
Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PZ-128
Intervention Type
DRUG
Placebo
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The subject is at least 18 years of age and may be of either sex/gender and of any race and ethnicity.
2. The subject is scheduled to undergo non-emergent PCI or non-emergent cardiac catheterization with the intention of performing PCI. The following classifications of the urgency of the procedure at the time the operator decides to perform it will be used for randomization stratification:
* Elective: The cardiac catheterization procedure ± PCI can be performed on an outpatient basis or during a subsequent hospitalization without significant risk of MI or death. For stable inpatients, this is a procedure that is performed during the hospitalization for convenience and ease of scheduling only and not because the subject's clinical situation demands that the procedure be performed prior to discharge.
OR
* Urgent: The cardiac catheterization ± PCI procedure should be performed on an inpatient basis and before discharge because of significant concerns about the risk of myocardial ischemia, MI and/or death. For subjects who are outpatients or in the emergency department at the time that the cardiac catheterization is requested, this is a procedure that would warrant hospital admission based on clinical presentation.
3. There is no anticipation that the subject would require treatment with a GP IIb/IIIa inhibitor prior to the initiation of the cardiac catheterization ± PCI procedure if the subject were not a participant in the current research study, and no anticipation of use during the procedure.
4. The subject is willing and able to give appropriate informed consent and complete all study-related procedures, and able to adhere to dosing and visit schedules (i.e., subject signs an approved informed consent document(s) and provides HIPAA authorization);
5. The subject will undergo all of the pre-enrollment parameters according to the study protocol prior to randomization and have them completed within 14 days prior to the scheduled cardiac catheterization ± PCI procedure and study drug administration.
6. Women of childbearing potential (all postmenarchal women who are \<1 year menopausal or who have not had surgical sterilization or a hysterectomy are considered to be women of child-bearing potential) must agree to use a medically accepted method of contraception from the time written informed consent is given up until 90 days following the study drug administration.
2. The subject is scheduled to undergo non-emergent PCI or non-emergent cardiac catheterization with the intention of performing PCI. The following classifications of the urgency of the procedure at the time the operator decides to perform it will be used for randomization stratification:
* Elective: The cardiac catheterization procedure ± PCI can be performed on an outpatient basis or during a subsequent hospitalization without significant risk of MI or death. For stable inpatients, this is a procedure that is performed during the hospitalization for convenience and ease of scheduling only and not because the subject's clinical situation demands that the procedure be performed prior to discharge.
OR
* Urgent: The cardiac catheterization ± PCI procedure should be performed on an inpatient basis and before discharge because of significant concerns about the risk of myocardial ischemia, MI and/or death. For subjects who are outpatients or in the emergency department at the time that the cardiac catheterization is requested, this is a procedure that would warrant hospital admission based on clinical presentation.
3. There is no anticipation that the subject would require treatment with a GP IIb/IIIa inhibitor prior to the initiation of the cardiac catheterization ± PCI procedure if the subject were not a participant in the current research study, and no anticipation of use during the procedure.
4. The subject is willing and able to give appropriate informed consent and complete all study-related procedures, and able to adhere to dosing and visit schedules (i.e., subject signs an approved informed consent document(s) and provides HIPAA authorization);
5. The subject will undergo all of the pre-enrollment parameters according to the study protocol prior to randomization and have them completed within 14 days prior to the scheduled cardiac catheterization ± PCI procedure and study drug administration.
6. Women of childbearing potential (all postmenarchal women who are \<1 year menopausal or who have not had surgical sterilization or a hysterectomy are considered to be women of child-bearing potential) must agree to use a medically accepted method of contraception from the time written informed consent is given up until 90 days following the study drug administration.
Exclusion Criteria
The subject will be excluded from entry if any of the criteria listed below are met:
(General Exclusions)
1. Subject is pregnant, intends to become pregnant or is breast-feeding (all women of child-bearing potential must have a negative pregnancy test result confirmed prior to randomization and it must be repeated to be within 24 hours prior to the study drug administration if necessary).
2. Any of the following allergy history(s):
* History of an allergic reaction\* or contraindication to any of the following protocol-directed drugs: aspirin, heparin, P2Y12 inhibitor (clopidogrel, prasugrel, ticagrelor), antihistamines (benadryl, famotidine); or
* History of an allergic reaction\* to contrast media; or
* History of an allergic reaction\* to a drug which required emergency medical treatment;
* History of an allergic reaction\* to a Hymenoptera sting which currently necessitates the subject to carry an EpiPen/injector or the subject has been prescribed one to treat an allergic reaction to a sting.
* An allergic (anaphylactic) reaction is characterized by an adverse local or general response from exposure to an allergen involving skin/mucosal tissue manifestations (hives, pruritus, flushing, angioedema), and/or respiratory compromise (dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia), and/or hemodynamic effects (hypo/hypertension, hypotonia, syncope).
3. Participation in another research study of investigational therapy (drug or device) within the past 30 days prior to randomization or planned use of other investigational therapy(s) during this research study (until 90 days following the study drug administration).
4. Subject is part of the study staff personnel directly involved with this trial, or is a family member of the study staff (clinical site or sponsor).
5. Prior enrollment (randomization) in this research study.
6. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the research study or which would, in the opinion of the investigator, unacceptably increase the subject's risk by participating in the research study. This would include, but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy or any unexplained blackouts.
(Exclusionary Prior/Concomitant Conditions)
7. Evidence of an ST-segment elevation myocardial infarction (STEMI) on presentation or during current hospitalization or a history of STEMI within the past 30 days prior to randomization.
8. Subject is scheduled to undergo PCI for known unprotected left main coronary artery (LMCA) disease (i.e., left main stenosis ≥50% not protected by at least 1 patent bypass graft).
9. Any history of a prior stroke (hemorrhagic or ischemic) or transient ischemic attack (TIA) of any etiology.
10. Cardiogenic or any type of shock on presentation or during current hospitalization (i.e., systolic blood pressure \<90 mm Hg requiring vasopressor or hemodynamic support).
11. History of heparin-induced thrombocytopenia (HIT).
12. Any active bleeding within the past 30 days prior to randomization.
13. Any condition or personal belief (e.g., Jehovah's Witness) which would interfere with the subject's ability or willingness to undergo a blood transfusion.
14. Any of the following conditions associated with increased risk of bleeding:
1. history of intracranial, intraocular, spinal, retroperitoneal or atraumatic intra- articular bleeding;
2. gastrointestinal bleeding within the past 30 days prior to randomization;
3. gastric or duodenal ulcer disease verified by endoscopy or barium meal contrast technique within the past 6 months prior to randomization;
4. history of bleeding disorder or diathesis;
5. major surgical procedure or trauma within the past 60 days prior to randomization or a planned surgical procedure to take place within 30 days following the study drug administration;
6. history or suspicion of intracranial neoplasm, arteriovenous malformation, or aneurysm; or
7. clinical finding(s) in the judgment of the investigator that poses an increased risk of bleeding.
15. Sustained severe hypertension: systolic blood pressure \>185 mm Hg or diastolic blood pressure \>105 mm Hg with or without anti-hypertensive treatment (as demonstrated by repeated BP measurements \>185/105 mm Hg including the final BP measurement before randomization).
16. Hypotension: systolic blood pressure \<95 mm Hg (as demonstrated by repeated systolic BP measurements \<95 mm Hg including the final systolic BP measurement prior to randomization).
17. Known active hepatobiliary disease, or known unexplained persistent increase in serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) activity to ≥2.5 times the upper limit of the reference range within the past 30 days prior to randomization.
18. Hemoglobin \<10 g/dL or hematocrit \<30%.
19. Platelet count \<75,000/mm3.
20. Stage 4-5 Chronic Kidney Disease (National Kidney Foundation) or on dialysis.
21. Active sepsis or suspected sepsis.
22. Body weight \<60 kg or \>175 kg.
23. Current evidence of invasive cancer (persistent disease excluding basal cell carcinoma of the skin) or treatment for invasive cancer within the past 6 months prior to randomization.
24. Left ventricular ejection fraction \<25% if known (any imaging technique) or New York Heart Association (NYHA) Class IV congestive heart failure.
(Exclusionary Prior/Concomitant/Anticipated Medication/Therapy)
25. Coronary interventional procedure of any kind within the past 30 days prior to randomization.
26. Anticipated subsequent staged multi-vessel PCI within 30 days following the study drug administration.
27. History of treatment with any parenteral GP IIb/IIIa inhibitor (GPI) within the past 30 days prior to randomization. (As stated in the Inclusion section, the planned treatment with a GPI prior to initiation of the cardiac catheterization ± PCI is not allowed; however, GPI for thrombotic bailout may be used during the PCI at the investigator's discretion).
28. Concurrent or anticipated treatment with a parenteral direct thrombin inhibitor (e.g., bivalirudin) for the cardiac catheterization ± PCI procedure.
29. History of treatment with another PAR1 inhibitor within the past 60 days prior to randomization or the concurrent/anticipated use after randomization up until 30 days following the study drug administration.
30. History of treatment with another IV anti-platelet drug within 30 days prior to randomization or the concurrent/anticipated use after randomization up until 30 days following the study drug administration.
31. Any of the following anticoagulant or thrombolytic/fibrinolytic treatment(s):
* History of treatment with warfarin within 5 days prior to randomization or the concurrent/anticipated use after randomization up until 2 days following the study drug administration; or
* History of treatment with oral Factor Xa or direct thrombin inhibitors within 2 days prior to randomization or the concurrent/anticipated use after randomization up until 2 days following the study drug administration; or
* History of treatment with thrombolytic/fibrinolytic agents within 7 days prior to randomization or the concurrent/anticipated use of any of those agents after randomization up until 30 days following the study drug administration.
(General Exclusions)
1. Subject is pregnant, intends to become pregnant or is breast-feeding (all women of child-bearing potential must have a negative pregnancy test result confirmed prior to randomization and it must be repeated to be within 24 hours prior to the study drug administration if necessary).
2. Any of the following allergy history(s):
* History of an allergic reaction\* or contraindication to any of the following protocol-directed drugs: aspirin, heparin, P2Y12 inhibitor (clopidogrel, prasugrel, ticagrelor), antihistamines (benadryl, famotidine); or
* History of an allergic reaction\* to contrast media; or
* History of an allergic reaction\* to a drug which required emergency medical treatment;
* History of an allergic reaction\* to a Hymenoptera sting which currently necessitates the subject to carry an EpiPen/injector or the subject has been prescribed one to treat an allergic reaction to a sting.
* An allergic (anaphylactic) reaction is characterized by an adverse local or general response from exposure to an allergen involving skin/mucosal tissue manifestations (hives, pruritus, flushing, angioedema), and/or respiratory compromise (dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia), and/or hemodynamic effects (hypo/hypertension, hypotonia, syncope).
3. Participation in another research study of investigational therapy (drug or device) within the past 30 days prior to randomization or planned use of other investigational therapy(s) during this research study (until 90 days following the study drug administration).
4. Subject is part of the study staff personnel directly involved with this trial, or is a family member of the study staff (clinical site or sponsor).
5. Prior enrollment (randomization) in this research study.
6. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the research study or which would, in the opinion of the investigator, unacceptably increase the subject's risk by participating in the research study. This would include, but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy or any unexplained blackouts.
(Exclusionary Prior/Concomitant Conditions)
7. Evidence of an ST-segment elevation myocardial infarction (STEMI) on presentation or during current hospitalization or a history of STEMI within the past 30 days prior to randomization.
8. Subject is scheduled to undergo PCI for known unprotected left main coronary artery (LMCA) disease (i.e., left main stenosis ≥50% not protected by at least 1 patent bypass graft).
9. Any history of a prior stroke (hemorrhagic or ischemic) or transient ischemic attack (TIA) of any etiology.
10. Cardiogenic or any type of shock on presentation or during current hospitalization (i.e., systolic blood pressure \<90 mm Hg requiring vasopressor or hemodynamic support).
11. History of heparin-induced thrombocytopenia (HIT).
12. Any active bleeding within the past 30 days prior to randomization.
13. Any condition or personal belief (e.g., Jehovah's Witness) which would interfere with the subject's ability or willingness to undergo a blood transfusion.
14. Any of the following conditions associated with increased risk of bleeding:
1. history of intracranial, intraocular, spinal, retroperitoneal or atraumatic intra- articular bleeding;
2. gastrointestinal bleeding within the past 30 days prior to randomization;
3. gastric or duodenal ulcer disease verified by endoscopy or barium meal contrast technique within the past 6 months prior to randomization;
4. history of bleeding disorder or diathesis;
5. major surgical procedure or trauma within the past 60 days prior to randomization or a planned surgical procedure to take place within 30 days following the study drug administration;
6. history or suspicion of intracranial neoplasm, arteriovenous malformation, or aneurysm; or
7. clinical finding(s) in the judgment of the investigator that poses an increased risk of bleeding.
15. Sustained severe hypertension: systolic blood pressure \>185 mm Hg or diastolic blood pressure \>105 mm Hg with or without anti-hypertensive treatment (as demonstrated by repeated BP measurements \>185/105 mm Hg including the final BP measurement before randomization).
16. Hypotension: systolic blood pressure \<95 mm Hg (as demonstrated by repeated systolic BP measurements \<95 mm Hg including the final systolic BP measurement prior to randomization).
17. Known active hepatobiliary disease, or known unexplained persistent increase in serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) activity to ≥2.5 times the upper limit of the reference range within the past 30 days prior to randomization.
18. Hemoglobin \<10 g/dL or hematocrit \<30%.
19. Platelet count \<75,000/mm3.
20. Stage 4-5 Chronic Kidney Disease (National Kidney Foundation) or on dialysis.
21. Active sepsis or suspected sepsis.
22. Body weight \<60 kg or \>175 kg.
23. Current evidence of invasive cancer (persistent disease excluding basal cell carcinoma of the skin) or treatment for invasive cancer within the past 6 months prior to randomization.
24. Left ventricular ejection fraction \<25% if known (any imaging technique) or New York Heart Association (NYHA) Class IV congestive heart failure.
(Exclusionary Prior/Concomitant/Anticipated Medication/Therapy)
25. Coronary interventional procedure of any kind within the past 30 days prior to randomization.
26. Anticipated subsequent staged multi-vessel PCI within 30 days following the study drug administration.
27. History of treatment with any parenteral GP IIb/IIIa inhibitor (GPI) within the past 30 days prior to randomization. (As stated in the Inclusion section, the planned treatment with a GPI prior to initiation of the cardiac catheterization ± PCI is not allowed; however, GPI for thrombotic bailout may be used during the PCI at the investigator's discretion).
28. Concurrent or anticipated treatment with a parenteral direct thrombin inhibitor (e.g., bivalirudin) for the cardiac catheterization ± PCI procedure.
29. History of treatment with another PAR1 inhibitor within the past 60 days prior to randomization or the concurrent/anticipated use after randomization up until 30 days following the study drug administration.
30. History of treatment with another IV anti-platelet drug within 30 days prior to randomization or the concurrent/anticipated use after randomization up until 30 days following the study drug administration.
31. Any of the following anticoagulant or thrombolytic/fibrinolytic treatment(s):
* History of treatment with warfarin within 5 days prior to randomization or the concurrent/anticipated use after randomization up until 2 days following the study drug administration; or
* History of treatment with oral Factor Xa or direct thrombin inhibitors within 2 days prior to randomization or the concurrent/anticipated use after randomization up until 2 days following the study drug administration; or
* History of treatment with thrombolytic/fibrinolytic agents within 7 days prior to randomization or the concurrent/anticipated use of any of those agents after randomization up until 30 days following the study drug administration.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Sponsor Role
collaborator
RTI International
OTHER
Sponsor Role
collaborator
Inova Fairfax Hospital
OTHER
Sponsor Role
collaborator
University of Massachusetts, Worcester
OTHER
Sponsor Role
collaborator
Tufts Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Athan Kuliopulos, MD, PhD
Role: STUDY_DIRECTOR
Tufts Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tufts Medical Center
Boston, Massachusetts, United States
Site Status
UMass Memorial Medical Center
Worcester, Massachusetts, United States
Site Status
Inova Heart and Vascular Institute, Inova Fairfax Hospital
Falls Church, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):189-97. doi: 10.1161/ATVBAHA.115.306777.
Reference Type
BACKGROUND
Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A, Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos A. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):1368-1380. doi: 10.1161/ATVBAHA.118.310967. Epub 2018 Apr 5.
Reference Type
RESULT
Kuliopulos A, Gurbel PA, Rade JJ, Kimmelstiel CD, Turner SE, Bliden KP, Fletcher EK, Cox DH, Covic L; TRIP-PCI Investigators. PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2990-3003. doi: 10.1161/ATVBAHA.120.315168. Epub 2020 Oct 8.
Reference Type
RESULT
Fletcher EK, Wang Y, Flynn LK, Turner SE, Rade JJ, Kimmelstiel CD, Gurbel PA, Bliden KP, Covic L, Kuliopulos A. Deficiency of MMP1a (Matrix Metalloprotease 1a) Collagenase Suppresses Development of Atherosclerosis in Mice: Translational Implications for Human Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2021 May 5;41(5):e265-e279. doi: 10.1161/ATVBAHA.120.315837. Epub 2021 Mar 25.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMC-PZ128-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Adjunctive, Low-dose tPA in Primary PCI for STEMI
NCT03335839
COMPLETED
PHASE3
Safety and Efficacy of Percutaneous Coronary Intervention Combined With Thrombolysis at Different Time
NCT03137212
UNKNOWN
NA
Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
NCT02770664
UNKNOWN
PHASE2
High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
NCT01835353
COMPLETED
PHASE3
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
NCT00527943
TERMINATED
PHASE3
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty
NCT00269893
COMPLETED
PHASE3
The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI
NCT02658838
UNKNOWN
PHASE4
Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)
NCT00251823
COMPLETED
PHASE3
Safety and Efficacy of Bivalirudin During Short-term Intervention of Non-infarction Related Artery After PPCI of STEMI
NCT04475835
UNKNOWN
NA
Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients
NCT02639143
COMPLETED
PHASE4
The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction
NCT00611169
COMPLETED
PHASE4
P3AMI Antiplatelet Trial
NCT02376283
COMPLETED
PHASE4
Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI
NCT02787317
UNKNOWN
PHASE4
A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
NCT01327183
COMPLETED
PHASE2
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
NCT07195812
NOT_YET_RECRUITING
PHASE4
Safety of TG100-115 for Heart Attack Treated With Angioplasty
NCT00103350
COMPLETED
PHASE1/PHASE2
Rivaroxaban - Percutaneous Coronary Intervention
NCT05541757
COMPLETED
Evaluation in STEMI Patients Using FDY-5301
NCT04837001
COMPLETED
PHASE3
Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack
NCT01539590
TERMINATED
PHASE2
Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy
NCT06861374
NOT_YET_RECRUITING
NA
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
NCT05881382
UNKNOWN
PHASE3
Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty
NCT02592694
UNKNOWN
PHASE4
Platelet Function Monitoring in Patients With Acute Myocardial Infarction
NCT01353261
COMPLETED
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
NCT04090281
UNKNOWN
PHASE4